Mutations, Sequencing, Resistance: Advances and Updates in Chronic Lymphocytic Leukemia

To participate in this activity, please:

The therapeutic landscape of chronic lymphocytic leukemia (CLL) has been transformed with the introduction of targeted therapies, providing the opportunity to utilize minimal residual disease (MRD) as an indicator of treatment response and prognostic marker. This 1-hour online, self-directed activity explores the treatment landscape through 9 complex, real-world clinical decisions to advance clinicians’ understanding and application of best evidence and practices. The unique educational design actively engages learners with content, as faculty provide an in-depth rationale for each decision, based on their extensive experience.

Course Credit:

1.00 AMA PRA Category 1 CreditTM

Dates:

Opens: 2024-02-29
Closes: 2025-02-28

Target Audience:

This activity was developed for pathologists, hematologists, and medical oncologists.

This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

    Presenting Faculty

  • Sameer A. Parikh, MBBS

    Associate Professor of Medicine
    Assistant Professor of Oncology
    Department of Internal Medicine
    Division of Hematology
    Mayo Clinic
    Rochester, Minnesota